CVS HEALTH Corp (CVS) is held by 13 of 149 tracked super-investor funds (144 filed in Q2) in 2026 Q2 13F filings, with 2 funds opening new positions, 2 funds adding, and 10 funds trimming or exiting versus the previous quarter. Insiders were net buyers over the last 90 days ($2.0M bought vs $0 sold). Latest close $81.35 as of Nov 18, 2026.
Data as of Nov 18, 2026 (prices) · 2026 Q2 13F filings (quarter ended Jun 30, 2026) · Latest Form 4: Nov 6, 2026 · Congress to Nov 16, 2026.
Fairfax Financial Holdings · Davis Advisors · Patient Capital Management — 13 tracked funds hold CVS. See all holders.
Insiders bought on the open market (1 purchase, $2.0M) vs 0 sales ($0). Latest buy: Nov 6, 2026. Insider trading
CONSTELLATION BRANDS, INC. (STZ) · AMERICAN INTERNATIONAL GROUP, INC. (AIG) · APA Corp (APA) · FIFTH THIRD BANCORP (FITB) · ISHARES RUSSELL 1000 ETF (IWB) — stocks the same funds also hold. See all related stocks.
| Fund | Portfolio weight | Shares | Change vs prev. quarter |
|---|---|---|---|
| Fairfax Financial Holdings | 10.63% | 2,712,000 | HELD Q3 filed Nov 16 |
| Davis Advisors | 5.27% | 11,865,916 | TRIMMED (-3.1%) Q3 filed Nov 10 |
| Patient Capital Management | 4.19% | 1,235,505 | TRIMMED (-9.0%) Q3 filed Nov 12 |
| Hillman Capital Management | 4.15% | 55,475 | TRIMMED (-17.8%) Q3 filed Nov 16 |
| Pzena Investment Management | 3.57% | 11,769,536 | TRIMMED (-14.5%) Q3 filed Oct 30 |
| Dodge & Cox Funds | 2.71% | 50,012,765 | TRIMMED (-3.4%) Q3 filed Nov 13 |
| GQG Partners | 1.53% | 7,955,411 | ADDED (+25136.8%) Q3 filed Nov 13 |
| Viking Global Investors | 1.08% | 3,663,361 | NEW Q3 filed Nov 16 |
| Ariel Investments | 0.75% | 730,110 | ADDED (+4.0%) Q3 filed Nov 13 |
| Oakmark Funds | 0.05% | 335,817 | TRIMMED (-32.0%) Q3 filed Nov 16 |
| Matrix Asset Advisors | 0.05% | 6,175 | HELD Q3 filed Oct 13 |
| DJE Kapital | 0.04% | 16,590 | NEW Q3 filed Nov 12 |
| Atalanta Sosnoff Capital | 0.01% | 5,960 | TRIMMED (-9.5%) Q3 filed Nov 10 |
| Maverick Capital | — | — | EXITED |
| Tweedy Browne | — | — | EXITED |
| Samlyn Capital | — | — | EXITED |
Source: SEC Form 13F filings, quarter ended Jun 30, 2026. Change labels compare each fund’s 2026 Q2 filing with its previous filing. Fund counts aggregate every share class mapped to this ticker.
Price change since quarter-end: -18.1% from the close on the first trading day after the quarter ended (Jul 1, 2026) to the latest close (Nov 17, 2026). 13F does not report purchase prices — this is the price change since the quarter-end close, not a gain on any fund’s actual purchase.
Filing season: the Q3 2026 13F tracker follows every tracked fund’s filing for the quarter ended Sep 30, 2026, with its biggest buys and sells.
Closing prices (unadjusted for dividends), last 2 years — 501 trading days to Nov 18, 2026. Dashed lines mark 13F filing deadlines. Source: Yahoo Finance daily bars.
Tracked funds holding this stock, by quarter (2016Q4–2017Q2, 3 quarters). Source: quarterly BEST lists from 13F filings — tracked funds only, not all filers. A stock appears here only if it ever made a quarterly BEST list.
| Institutions holding | 2,075 of 8,857 filers |
| Long-only filers among them | 2,062 |
| Change vs 2026 Q1 | +225 net · 1,631 entered · 1,406 exited |
| Shares reported, all filers | 1,130,618,041 |
| Reported value, all filers | $115.0B |
Source: SEC Form 13F data sets — every filer's latest report for the quarter ended Jun 30, 2026, not just the tracked funds above; changes compare with the quarter ended Mar 31, 2026. Share counts and values are summed as reported in the filings (a small number of filers report values in thousands of dollars, so value totals are as-filed sums).
| Exchange | NYSE |
| Industry | Retail-Drug Stores and Proprietary Stores (SIC 5912) |
| Revenue · FY2025 | $402.1B |
| Net income · FY2025 | $1.8B |
| Total assets · FY2025 | $253.5B |
| Shares outstanding | 1,278,970,369 |
| Market cap (at latest close) | $104.0B |
Source: SEC EDGAR company filings (submissions and company facts), collected Oct 30, 2026. Shares outstanding as reported Jul 29, 2026.
| Shares short · Oct 15, 2026 | 16,193,404 |
| Share of shares outstanding | 1.27% |
| Days to cover | 1.57 |
Shares short at recent settlements — Jul 31, 2026: 18.7M · Aug 14, 2026: 16.8M · Aug 31, 2026: 18.1M · Sep 15, 2026: 16.1M · Sep 30, 2026: 16.5M · Oct 15, 2026: 16.2M.
Source: FINRA Equity Short Interest (biweekly settlement data). Shares outstanding from SEC filings as of Jul 29, 2026.
| Shares failed to deliver · Oct 14, 2026 | 0 |
| Share of shares outstanding | 0.00% |
| Fails as a share of short interest · Oct 15, 2026 | 0.0% |
Fails to deliver at recent settlements — Jul 31, 2026: 0 · Aug 14, 2026: 0 · Aug 31, 2026: 0 · Sep 15, 2026: 0 · Sep 30, 2026: 0 · Oct 14, 2026: 0.
Source: SEC Fails-to-Deliver data (semi-monthly files, published about two weeks after each settlement date). Each figure is the balance of shares not yet delivered on that date; a stock absent from that date’s file counts as zero. See our research on whether fails to deliver predict returns. Shares outstanding from SEC filings as of Jul 29, 2026.
1 insider bought on the open market in the last 90 days (1 purchase, $2.0M), against 0 sales by 0 insiders ($0). Latest buy: Nov 6, 2026.
$1M+ open-market buySource: SEC Form 4 filings. Open-market transactions only.
| Latest open-market buy | Transaction price | Price change since disclosure |
|---|---|---|
| Shah Prem S · 23,855 shares on Nov 6, 2026 · filed Nov 6, 2026 | $83.89 | +0.7% (close Nov 9, 2026 → Nov 17, 2026) |
Reference close is the first trading day after the filing (Nov 9, 2026). The transaction price is what the insider paid; the price change is on closing prices (dividends excluded).
Recent open-market trades
| Date | Insider | Role | Buy / Sell | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| Nov 6, 2026 | Shah Prem S | EVP and Group President | Buy | 23,855 | $83.89 | $2.0M | SEC filing |
Most recent open-market transactions in the same 90-day window, most recent first. Source: SEC Form 4 filings.
| Filed | Seller | Role | Shares to sell | Market value | Approx. sale date | Source |
|---|---|---|---|---|---|---|
| May 22, 2026 | AGUIRRE FERNANDO | Director | 2,263 | $214.3K | May 20, 2026 | SEC filing |
| May 21, 2026 | FARAH ROGER N | Director | 2,817 | $263.9K | May 21, 2026 | SEC filing |
| May 8, 2026 | TILAK MANDADI | Officer | 69,551 | $6.2M | May 8, 2026 | SEC filing |
| Aug 19, 2025 | Finucane Anne A. | Director | 7,500 | $532.3K | Aug 20, 2025 | SEC filing |
| Mar 5, 2025 | Clark James David | Officer | 7,513 | $498.5K | Mar 5, 2025 | SEC filing |
| Feb 16, 2024 | PREM S SHAH | Officer | 29,473 | $2.3M | Feb 16, 2024 | SEC filing |
| Aug 3, 2023 | Clark James David | Officer | 25,759 | $1.9M | Aug 3, 2023 | SEC filing |
A Form 144 notice is a planned sale, not a completed sale. Most recent first. Source: SEC Form 144 filings, 63,013 notices from Apr 13, 2023 to Oct 9, 2026.
| Filed | Filer | Form | Shares | % owned | Event date | Source |
|---|---|---|---|---|---|---|
| Aug 13, 2026 | Dodge & Cox | SC 13G/A | 50,012,765 | 3.9% | Jun 30, 2026 | SEC filing |
| Apr 29, 2026 | Vanguard Capital Management | SC 13G | 95,598,528 | 7.5% | Mar 31, 2026 | SEC filing |
| Mar 26, 2026 | The Vanguard Group | SC 13G/A | 0 | 0.0% | Mar 13, 2026 | SEC filing |
| Jul 16, 2025 | BlackRock, Inc. | SC 13G/A | 105,292,588 | 8.3% | Jun 30, 2025 | SEC filing |
| May 13, 2025 | Capital World Investors | SC 13G | 68,785,990 | 5.5% | Mar 31, 2025 | SEC filing |
| Apr 17, 2025 | BlackRock, Inc. | SC 13G/A | 89,218,268 | 7.1% | Mar 31, 2025 | SEC filing |
One filing is one row; a filing may list several reporters and the first is shown. Figures are as filed, including amendments that report zero shares after a transfer. Source: SEC Schedule 13D/G filings, 57,443 filings parsed to Oct 2, 2026.
Data unavailable — no congressional STOCK Act transactions for this ticker were parsed in the current window (as of Nov 16, 2026).
Industry: Retail-Drug Stores and Proprietary Stores (SIC 5912). No standing committee maps to this industry under the site’s jurisdiction rule — see Methodology.
Assignments are the current (119th Congress) rosters. A trade made in an earlier Congress may have been made under a different assignment. Jurisdiction is by industry (SEC SIC code), not by anything the company said or did. Same rule as our committee-jurisdiction study.
Lobbying: no Lobbying Disclosure Act filings matched for this ticker (1999–2026).
Federal contracts: $597.4M in obligated amounts, fiscal years 2021–2026.
| Fiscal year | Obligated amount |
|---|---|
| FY2021 | $78.5M |
| FY2022 | $355.7M |
| FY2023 | $130.1M |
| FY2024 | $20.2M |
| FY2025 | $7.1M |
| FY2026 | $5.8M |
Largest awards collected
| Award ID | Agency | Amount | Start |
|---|---|---|---|
| 75A50121C00090 | Department of Health and Human Services | $498.2K | Sep 30, 2021 |
| 36C25222P0236 | Department of Veterans Affairs | $45.1K | Dec 22, 2021 |
| 15B30224P00000151 | Department of Justice | $26.6K | Feb 12, 2024 |
| 36C24122P0929 | Department of Veterans Affairs | $26.2K | Aug 31, 2022 |
| 68HERC22P0026 | Environmental Protection Agency | $20.0K | Feb 15, 2022 |
Lobbying filings are matched by company core name; a filing can match more than one ticker. Contract amounts are obligated amounts (money committed, not money spent), matched by recipient name — contracts under a subsidiary’s name can be missed. Sources: Senate Lobbying Disclosure Act filings; USAspending.gov. See Methodology.
Insiders
· Large Insider Buys — Last 90 days: a single buy trade of $1M or more
· Insider Net Buying — Last 90 days: more insider buy transactions than sell transactions
Financial Screens
· Growth — Revenue up every year for 5 straight years
· Dividend Growth — Dividends raised for more than 10 years
· Cash Flow (FCF) — Positive free cash flow in each of the last 3 years, with an FCF yield of at least 5%
· Earnings Quality (Cash Conversion) — Profits that actually come back as cash
Red Flags
· Distress Risk (Altman Z″) — Altman Z″-Score below 1.10
Key figures
· Growth — Latest revenue: $402.1B · 5-yr revenue CAGR: 8.4% · Straight growth years: 15
· Dividend Growth — Dividend per share: 2.66 · Dividend yield: 2.9% · Straight dividend years: 19 · 10-yr dividend growth: 56.5%
· Cash Flow (FCF) — Latest FCF: $7.8B · FCF yield: 6.8% · Positive FCF years: 3
· Earnings Quality (Cash Conversion) — Cash conversion (3-yr avg): 3.20 · Operating cash flow: $10.6B · Net income: $1.8B
· Large Insider Buys — Buy value: $2.0M · Buy txns: 1 · Insiders buying: 1 · Latest buy: Nov 6, 2026
· Insider Net Buying — Buy txns: 1 · Sell txns: 0 · Buy value: $2.0M · Latest buy: Nov 6, 2026
· Distress Risk (Altman Z″) — Z″-Score: 0.99 · Working capital / assets: -0.06 · Retained earnings / assets: 0.24 · EBIT / assets: 0.02 · Equity / liabilities: 0.42
Financial screens are computed from SEC company financial statements; red-flag models are screens, not verdicts — see Methodology.
· Super-investor 13F BEST — appeared in 3 of the last 40 quarterly lists; latest 2017 Q2, ranked #44 of 50.
· Insider BEST — appeared in 1 of the last 20 quarterly lists; latest 2024 Q2, ranked #44 of 50.
· Politician BEST — appeared in 1 of the last 20 quarterly lists; latest 2021 Q4, ranked #16 of 50.
| 13F signal (2021 Q3 – 2026 Q1) | Events | Win rate | Avg return | SPY | Excess |
|---|---|---|---|---|---|
| Heavy accumulation — 3+ tracked funds increased together | 14 | 57.1% | +3.3% | +2.8% | +0.5% |
| Share count tripled (3x) | 3 | 66.7% | +3.1% | +4.8% | -1.7% |
Measured from SEC 13F filings: entry at the close on the first trading day after each quarter’s filing deadline, exit one quarter later on the same rule, dividend-adjusted closes. Past records do not guarantee future results — see Track Record and Methodology.
Also held by the tracked funds that hold CVS — ranked by lift, the co-holding pattern described in Methodology: CONSTELLATION BRANDS, INC. (STZ) · AMERICAN INTERNATIONAL GROUP, INC. (AIG) · APA Corp (APA) · FIFTH THIRD BANCORP (FITB) · ISHARES RUSSELL 1000 ETF (IWB) · M&T BANK CORP (MTB) · UBS Group AG (UBS) · Corebridge Financial, Inc. (CRBG).
Filings audit: every filing lens on CVS HEALTH Corp (CVS), scored — GetCoattail Research.
| Filed | Items | Source |
|---|---|---|
| Nov 4, 2026 | 7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits | SEC filing |
| Nov 4, 2026 | 2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits | SEC filing |
| Aug 17, 2026 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers · 7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits | SEC filing |
Source: SEC EDGAR Form 8-K filings, latest first. Amendments (Form 8-K/A) are labeled as such. Item labels are the SEC's item titles; a filing can carry several items. Item 5.02 covers both departures and appointments, which this index does not distinguish.
CONSTELLATION BRANDS, INC. (STZ) · Filings audit: every filing lens on CVS HEALTH Corp (CVS), scored · Practice timing on CVS
One email a week: the week’s new filings and research. Subscribe free
Open the interactive tool →Live screens, charts and backtests for every tracked stock, fund and signal — free, no sign-up.